News in brief: Shire's Canadian merger delayed

UK company Shire Pharmaceuticals has said that its proposed $3.5bn (€3.9bn) merger with Canadian firm BioChem will be delayed.

A review period for the merger ends on March 31, but the Canadian minister of industry said that he would not be able to reach a conclusion by that time. Merrill Lynch is financial adviser to BioChem as well as being joint broker to Shire. Deutsche Bank and Bear Stearns are advising Shire.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump